Credit Suisse Upgrades Medtronic (MDT) to Outperform
More News related to MDT
- Medtronic CEO William Hawkins to Speak at 21st Annual Piper Jaffray Healthcare Conference
- Highlights From MDT's Q3 Conference Call: U.S. Revenues up 5%, International Sales Up 13%; Guides Above for FY10
- Medtronic's (MDT) Earnings and Guidance Shows A Strong Heart Beat
- Medtronic (MDT) Tops Q3 Views; Guides FY10 EPS Above the Street
- Medtronic Second Quarter Revenue Increases 8% to $3.838 Billion; Raises EPS Guidance for Current Fiscal Year
More News related to Upgrades
- Canaccord Adams Maintains a 'Buy' on Protalix BioTherapeutics (PLX); Cerezyme Supply on Track, See More Uplyso EAP Uptake
- Bove Says US Banking System, Dollar to Benefit from Dubai Crisis
- Broadpoint.AmTech Says Solar Inventory Getting Healthier into Year-end
- UBS Maintains a Neutral rating on American Eagle Outfitters (AEO); Lowers Estimates Through 2011
- Barclays Reiterates an 'Overweight' on Deere (DE); Adjusts Estimates & PT
Credit Suisse upgrades Medtronic, Inc. (NYSE: MDT) from Neutral to Outperform.
Medtronic, Inc. develops, manufactures, and sells device-based medical therapies worldwide.
Related Categories
UpgradesStocks Mentioned
-0.19Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
